Prothena Corporation plc $PRTA Position Boosted by American Century Companies Inc.

American Century Companies Inc. grew its holdings in shares of Prothena Corporation plc (NASDAQ:PRTA) by 14.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 34,836 shares of the biotechnology company’s stock after purchasing an additional 4,437 shares during the period. American Century Companies Inc.’s holdings in Prothena were worth $431,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Prothena by 6.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,269 shares of the biotechnology company’s stock worth $381,000 after buying an additional 1,551 shares during the last quarter. ProShare Advisors LLC grew its position in Prothena by 29.5% in the fourth quarter. ProShare Advisors LLC now owns 14,524 shares of the biotechnology company’s stock worth $201,000 after buying an additional 3,312 shares during the last quarter. Chicago Partners Investment Group LLC grew its position in Prothena by 29.6% in the first quarter. Chicago Partners Investment Group LLC now owns 14,512 shares of the biotechnology company’s stock worth $180,000 after buying an additional 3,315 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Prothena by 4,626.0% during the 1st quarter. GAMMA Investing LLC now owns 6,002 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 5,875 shares in the last quarter. Finally, Hsbc Holdings PLC boosted its stake in shares of Prothena by 60.4% during the 4th quarter. Hsbc Holdings PLC now owns 24,179 shares of the biotechnology company’s stock worth $323,000 after acquiring an additional 9,101 shares in the last quarter. Institutional investors own 97.08% of the company’s stock.

Prothena Stock Performance

Shares of PRTA opened at $8.55 on Friday. The company’s 50 day moving average price is $7.32 and its 200 day moving average price is $8.80. Prothena Corporation plc has a 52 week low of $4.32 and a 52 week high of $22.71. The company has a market capitalization of $460.25 million, a PE ratio of -1.52 and a beta of -0.04.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported ($1.86) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.75). Prothena had a negative net margin of 2,929.30% and a negative return on equity of 62.17%. The company had revenue of $4.42 million for the quarter, compared to analysts’ expectations of $5.36 million. On average, equities analysts forecast that Prothena Corporation plc will post -4.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on PRTA. Cantor Fitzgerald reissued a “neutral” rating on shares of Prothena in a research note on Friday, June 20th. Piper Sandler dropped their price target on Prothena from $81.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, August 28th. Bank of America reissued an “underperform” rating on shares of Prothena in a research note on Wednesday, May 28th. Royal Bank Of Canada dropped their target price on shares of Prothena from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Tuesday, August 5th. Finally, Chardan Capital reissued a “buy” rating and issued a $18.00 target price on shares of Prothena in a research report on Thursday, August 28th. Four investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $19.75.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.